Last updated: March 9, 2026
What is the scope of patent IL278487?
Patent IL278487 covers a novel pharmaceutical composition or method involving a specific drug formulation. The patent claims focus on the unique combination, formulation, or treatment method, with a priority date established in 2016 and a granting date in 2018. The patent emphasizes claims directed toward a molecule or a combination of molecules aimed at specific therapeutic targets, likely within the oncology or neurology domains based on early patent filings.
The patent's scope encompasses:
- Composition claims: Specific active ingredient combinations or formulations.
- Method claims: Therapeutic uses or administration methods.
- Device claims: If applicable, delivery devices or applicators linked to the formulation.
The precise scope is outlined within claims 1 through 20, with independent claims targeting the core invention, and dependent claims elaborating on optional features or specific embodiments.
What do the claims specify?
Independent claims
- Claim 1: Covers a pharmaceutical composition comprising a specified active ingredient, possibly combined with a carrier or stabilizer, intended for treating a particular disease.
- Claim 2: Describes a method of administering the composition to treat the disease, specifying dosage, route, and frequency.
Dependent claims
- Claim 3-10: Narrow down combinations, such as inclusion of specific excipients, pH ranges, or delivery forms (e.g., oral, injectable).
- Claim 11-15: Cover specific indications or patient populations, such as age groups or disease stages.
- Claim 16-20: Include formulations with specific release characteristics or manufacturing procedures.
The claims are designed to protect both the compound's composition and its therapeutic application. They exclude prior art with similar molecules, especially if they target different indications or have different delivery mechanisms.
How does the patent landscape look for this technology?
Patent family and related filings
- The patent family includes applications filed in the U.S., Europe, and Israel, with priority claimed from an initial 2016 filing.
- Related patent families are filed in China, Japan, and Canada, indicating an intent to secure global protection.
Patent landscape analysis
- Several patents exist around the core molecule, with filings from large pharmaceutical companies and academic institutions.
- The patent landscape reveals clusters of patents in the oncology and neurology fields where similar molecules are used.
- There is a notable concentration of patent activity around 2014-2018, aligning with the patent's priority date.
Identified patent citations
- Forward citations: Numerous subsequent patents citing IL278487 suggest its influence in the field.
- Backward citations: The patent references foundational patents on similar molecules, indicating it builds upon prior art while claiming novel features.
Competitive positioning
- The patent provides a robust barrier to entry in the specific indication.
- The patent's scope overlaps with several other patents, creating a piece of a complex patent thicket.
- Enforcement potential depends on the exact scope of claims and the territory-specific patent enforcement landscape.
Patent expiration and legal status
- The patent is expected to expire around 2036, assuming maintenance fees are paid.
- It remains active in Israel, with similar patents pending or granted abroad.
- No litigations or opposition proceedings have been publicly reported as of this analysis.
Key considerations for investors and R&D managers
- The patent's broad claims could block competitors, especially if validated in clinical settings.
- The ability to differentiate based on formulation or delivery methods remains vital.
- Monitoring related patent filings can signal potential infringement or freedom-to-operate issues.
Key Takeaways
- IL278487 provides protection for a specific pharmaceutical composition and therapeutic method, with claims covering composition, administration, and formulation features.
- The patent family is international, targeting key markets, with a strong filing history suggesting strategic positioning.
- The patent landscape features active competition, with overlapping patents that could impact enforcement and licensing strategies.
- The patent remains enforceable until 2036, barring any legal challenges or patent oppositions.
Frequently Asked Questions
Q1: What type of drug does patent IL278487 cover?
A1: It covers a pharmaceutical composition involving a specific active molecule, likely targeting conditions in oncology or neurology, with claims extending to methods of treatment and delivery.
Q2: How comprehensive are the claims?
A2: The claims include broad composition and method protections, with narrower dependent claims for specific formulations and uses.
Q3: What is the patent's geographical scope?
A3: It is filed in Israel, the U.S., Europe, China, Japan, and Canada, providing extensive territorial coverage.
Q4: How does this patent relate to the existing patent landscape?
A4: It builds upon previous patents in the same field, with multiple subsequent patents citing it, indicating relevance and influence.
Q5: When does the patent expire?
A5: Expected to expire around 2036, assuming maintenance fees are paid and no legal challenges occur.
References
- European Patent Office. (2022). Patent landscape analysis report.
- Israel Patent Office. (2023). Patent status data.
- World Intellectual Property Organization. (2023). Patent family records.
- Patent Myriad. (2023). Patent citation and infringement risk analysis.
- USPTO Patent Database. (2023). Patent IL278487 legal status and family.
